In the present study a new co-crystal of Ticagrelor with L-Tartaric acid has been prepared with improved solubility.
Ticagrelor is a class VI drug with poor solubility and permeability; hence an attempt has been made to improve its solubility
by co-crystallization technology.A co-crystal is a structurally homogeneous crystalline material containing an API and the
co-former in definite stoichiometric amounts. In this study the conformer selected was L-Tartaric acid based on ease of
hydrogen bond formation. The co-crystal of Ticagrelor with L-Tartaric acid was prepared in different ratios (1:1, 2:1, 1:2).
Ticagrelor formed stable co-crystals in the ratios 1:1and2:1. The formation of co-crystal was confirmed by FTIR, DSC and
PXRD. The dynamic solubility of co-crystals in the ratios 1:1 and 2:1 was increased by approximately 2.7 and 2.6 fold
respectively as compared to pure drug. The in-vitrodissolution study demonstrated a 1.5 fold increase in the solubility for
selected TIC:L-TAR (1:1) as compared to its TIC active pharmaceutical ingredient and TIC physical mixture.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.